CINCINNATI, Oct. 4 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced that President and Chief Operating Officer Christopher C. Bergen will participate in the Natixis Bleichroeder Hidden Gems Conference. The conference will be held at The Carlton on Madison Avenue in New York City, Oct. 8-9, 2007. Kendle's presentation is scheduled for Monday, Oct. 8 at 2:15 p.m. Eastern Time.
The public is invited to listen to a live webcast of Kendle's presentation at http://www.kendle.com (click on the link provided in the Investor Events section) or at http://www.wsw.com/webcast/nblr/kndl/. An archived version can be accessed following Kendle's presentation and will be available through Nov. 8.
Slides accompanying the presentation will be available by 9 a.m. Eastern Time on Oct. 8 at http://www.kendle.com in the Investor Relations section.
Kendle International Inc. (Nasdaq: KNDL) is among the world's leading global clinical research organizations and is the fourth-largest provider of Phase II-IV clinical development services worldwide. We deliver innovative and robust clinical development solutions -- from first-in-human studies through market launch and surveillance -- to help the world's biopharmaceutical companies maximize product life cycles and grow market share.
Our global clinical development business is focused on five regions -- North America, Europe, Asia/Pacific, Latin America and Africa -- to meet customer needs. With the expertise of our more than 3,000 associates worldwide, Kendle has conducted clinical trials and provided regulatory and pharmacovigilance services in more than 80 countries. The company was named the "Top CRO to Work With" in the Thomson CenterWatch 2007 Survey of U.S. Investigative Sites.
Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at http://www.kendle.com.
|SOURCE Kendle International Inc.|
Copyright©2007 PR Newswire.
All rights reserved